The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 10, 2024
Filed:
Apr. 22, 2021
Enhanced antigen presenting ability of rna car t cells by co-introduction of costimulatory molecules
Applicants:
Novartis Ag, Basel, CH;
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Inventors:
Yangbing Zhao, Lumberton, NJ (US);
Devon J. Shedlock, Philadelphia, PA (US);
Carl H. June, Merion Station, PA (US);
Xiaojun Liu, Swarthmore, PA (US);
Assignees:
Novartis AG, Basel, CH;
The Trustees of the University of Pennsylvania, Philadelphia, PA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/02 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70517 (2013.01); A61K 39/0011 (2013.01); A61K 39/02 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); C07K 14/54 (2013.01); C07K 14/5418 (2013.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70532 (2013.01); C07K 14/70575 (2013.01); C07K 14/70596 (2013.01); C07K 16/28 (2013.01); C12N 5/0638 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); G01N 33/505 (2013.01); A61K 38/00 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/53 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01); C12N 2501/51 (2013.01); C12N 2501/515 (2013.01); C12N 2510/00 (2013.01); C12N 2760/16034 (2013.01);
Abstract
The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.